written on 30.04.2014

With Big Pharma mergers in the works, whose SG&A costs look ripe for cutting?


When Big Pharma starts talking about big buyouts, the sales and marketing departments start chattering about their jobs. Last week's Novartis-plus-GlaxoSmithKline cancer deal is one prime example. Another, bigger one: Pfizer's proposed $100-billion-or-so buyout of AstraZeneca.